Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupropion SR and Counseling for Smoking Cessation
NCT01621009Phase 4Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Jan 2001
- Primary completion
- Oct 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of bupropion in tobacco dependence (4 arms), sponsored by University of Wisconsin–Madison. Primary endpoint: 7-day Point Prevalence Abstinence From Smoking at 6 Months. Started Jan 2001; status: completed.
02
Drugs
bupropion
03
Conditions
tobacco dependence
Beyond the preview
Go deeper on NCT01621009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01621009.